admin

GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).

Did you know… The U.S. Department of Health and Human Services is one of the largest sources of early-stage capital for life sciences in the U.S.? There is more than $1.2 billion of seed funding for small businesses that are developing innovative products and services that could potentially save lives.

Seraxis, which is currently located at the Pinkney Innovation Complex for Science & Technology at Montgomery College (PIC MC) in the County-owned Germantown Innovation Center is developing its lead therapy, SR-01, to eliminate the need for type 1 diabetes patients to inject insulin. SR-01 is a revolutionary therapy that could impact more than 4.5 million people in the world. 

The Seraxis solution is a simple approach to diabetes. Chief Executive Officer Dr. William Rust explained that the therapy replaces damaged or lost insulin-producing pancreatic cells with those grown in the Seraxis labs. In order to accomplish this, Seraxis has developed a proprietary human stem cell line dubbed SR1423 which is special. 

Every year or so at Crunchbase News, we take a look at which U.S. universities graduate the highest number of funded startup founders. And each time, we find few surprises in the top rankings.

The leading schools for funded founders are reliably Stanford, Harvard and MIT. The top regions are California and the Northeast. And the top business schools are Harvard, Stanford and Wharton.

Image: https://news.crunchbase.com

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 1, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved Tyvaso® (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. This is the second FDA-approved indication for Tyvaso, which was first approved in July 2009 for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.

The U.S. Department of Health and Human Services launched an innovation challenge competition today encouraging American inventors to aid the nation’s COVID-19 response by designing effective, comfortable face masks for personal use that resolve the common complaints people have about wearing masks. The contest taps into the nation’s creativity and entrepreneurial spirit to help curb the spread of SARS-CoV-2, the virus that causes COVID-19.

Image: https://www.medicalcountermeasures.gov

To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.

Peter Meath, Co-Head of Healthcare and Life Sciences for Commercial Banking, notes that investment in life sciences reached record-high levels across almost every category and subsector—despite unprecedented business challenges. Here are a few of the highlights: 

Image: https://www.jpmorgan.com